Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect

Clinical Research in Cardiology

Volumn 105, Issue 6, 2016, Pages 489-507

  Ferreira, João Pedro ^a,b   Girerd, Nicolas ^a   Medeiros, Pedro Bettencourt ^c   Santos, Mário ^b,c   Carvalho, Henrique Cyrne ^c   Bettencourt, Paulo ^d   Kénizou, David ^e   Butler, Javed ^f   Zannad, Faiez ^a   Rossignol, Patrick ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b University of Porto   (Portugal)

^c Centro Hospitalar Universitario do Porto   (Portugal)

^d Centro Hospitalar Universitário de São João   (Portugal)

^e Hôpitaux Universitaires de Strasbourg   (France)

^f STONY BROOK UNIVERSITY   (United States)

Author keywords

Acutely decompensated heart failure; Outcomes; Spironolactone; Spot urinary sodium

Indexed keywords

ALDOSTERONE; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CREATININE; ELECTROLYTE; FUROSEMIDE; HEMOGLOBIN; MINERALOCORTICOID ANTAGONIST; POTASSIUM; POTASSIUM ION; SODIUM; SODIUM ION; SPIRONOLACTONE; UREA; LOOP DIURETIC AGENT;

ACUTE HEART FAILURE; AGE; AGED; ARTICLE; ASCITES; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DYSPNEA; EDEMA; ELECTROLYTE URINE LEVEL; FEMALE; FOLLOW UP; GENDER; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOKALEMIA; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PROGNOSIS; SODIUM EXCRETION; SODIUM URINE LEVEL; TREATMENT RESPONSE; URINALYSIS; VERY ELDERLY; CHI SQUARE DISTRIBUTION; CONTROLLED CLINICAL TRIAL; DRUG EFFECTS; FRANCE; HEART FAILURE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NATRIURESIS; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; URINE;

AGED; AGED, 80 AND OVER; BIOMARKERS; CHI-SQUARE DISTRIBUTION; FEMALE; FRANCE; HEART FAILURE; HOSPITALIZATION; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MULTIVARIATE ANALYSIS; NATRIURESIS; POTASSIUM; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SODIUM; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; TIME FACTORS; TREATMENT OUTCOME; URINALYSIS;

EID: 84948691058     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-015-0945-x     Document Type: Article

References (57)

1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A (2012) ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 14:803–869
2. Ellison DH (2001) Diuretic therapy and resistance in congestive heart failure. Cardiology 96(3–4):132–143
3. Gekle M, Grossmann C (2009) Actions of aldosterone in the cardiovascular system: the good, the bad, and the ugly? Pflugers Arch 458(2):231–246
4. Schrier RW (2008) Blood urea nitrogen and serum creatinine: not married in heart failure. Circ Heart Fail 1:2–5
5. Wilcox CS, Mitch WE, Kelly RA, Skorecki K, Meyer TW, Friedman PA, Souney PF (1983) Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 102:450–458
6. Kociol RD, McNulty SE, Hernandez AF, Lee KL, Redfield MM, Tracy RP, Braunwald E, O’Connor CM, Felker GM (2012) Markers of decongestion, dyspnea relief and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail
7. Iyengar S, Abraham WT (2006) Diuretic resistance in heart failure. Curr Heart Fail Rep 3(1):41–45
8. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, Gheorghiade M, Fiuzat M, Rossignol P, Zannad F, Pitt B, O’Connor C, Felker GM (2014) Decongestion in acute heart failure. Eur J Heart Fail 16(5):471–482
9. Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, Tang WH (2014) Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. J Card Fail 20(6):392–399
10. Alexander WD, Branch RA, Levine DF, Hartog M (1977) The urinary sodium: potassium ratio and response to diuretics in resistant oedema. Postgrad Med J 53(617):117–121
11. Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, Loria P, Banker ME, Piotrowski DW, Boustany-Kari CM (2011) The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. J Transl Med 9:180
12. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H (2013) Tailoring diuretic therapy in acute heart failure: insight into early diuretic response predictors. Clin Res Cardiol 102(10):745–753
13. Edmonds CJ (1960) An aldosterone antagonist and diuretics in the treatment of chronic oedema and ascites. Lancet 1(7123):509–515
14. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F (2011) Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol 58(19):1958–1966
15. Albaghdadi M, Gheorghiade M, Pitt B (2011) Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes. Eur Heart J 32(21):2626–2633
16. Bansal S, Lindenfeld J, Schrier RW (2009) Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist? Circ Heart Fail. 2(4):370–376
17. Ferreira JP, Santos M, Almeida S, Marques I, Bettencourt P, Carvalho H (2013) Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med. 25(1):67–72
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 130:461–470
19. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Cleland JG, Cohn JN, Dickstein K, Domanski MJ, Ekman I, Filippatos GS, Gheorghiade M, Hernandez AF, Jaarsma T, Koglin J, Konstam M, Kupfer S, Maggioni AP, Mebazaa A, Metra M, Nowack C, Pieske B, Piña IL, Pocock SJ, Ponikowski P, Rosano G, Ruilope LM, Ruschitzka F, Severin T, Solomon S, Stein K, Stockbridge NL, Stough WG, Swedberg K, Tavazzi L, Voors AA, Wasserman SM, Woehrle H, Zalewski A, McMurray JJ (2013) Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail 15(10):1082–1094
20. Ricci Z, Cruz DN, Ronco C (2011) Classification and staging of acute kidney injury: beyond the RIFLE and AKIN criteria. Nat Rev Nephrol 7:201–208
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
22. Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27(2): 157–172, 207–112
23. Uno H, Tian L, Cai T, Kohane IS, Wei LJ (2013) A unified inference procedure for a class of measures to assess improvement in risk prediction systems with survival data. Stat Med 32(14):2430–2442
24. Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361–387
25. Kang L, Chen W, Petrick NA, Gallas BD (2015) Comparing two correlated C indices with right-censored survival outcome: a one-shot nonparametric approach. Stat Med 34(4):685–703
26. Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111:2837–2849
27. Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN (1984) The neurohumoral axis in congestive heart failure. Ann Intern Med 101(3):370–377
28. Struthers AD (2002) Aldosterone: cardiovascular assault. Am Heart J 144:S2–S7
29. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, Struthers AD, Voors AA, Ruilope LM, Bakris GL, O’Connor CM, Gheorghiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, Filippatos GS, Massy ZA, Pathak A, Piña IL, Sabbah HN, Sica DA, Tavazzi L, Pitt B (2012) Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 33(22):2782–2795
30. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341(10):709–717
31. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11–21
32. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321
33. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392
34. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B (2015) Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131(1):34–42
35. Rossignol P, Zannad F (2015) Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but East does not meet west. Circulation 131:7–10
36. Ferreira JP, Girerd N, Rossignol P, Zannad F (2015) Geographic differences in heart failure trials. Eur J Heart Fail
37. Eng M, Bansal S (2014) Use of natriuretic-doses of spironolactone for treatment of loop diuretic resistant acute decompensated heart failure. Int J Cardiol 170(3):e68–e69
38. Girerd N, Collier T, Pocock S, Krum H, McMurray JJ, Swedberg K, Van Veldhuisen DJ, Vincent J, Pitt B, Zannad F (2015) Clinical benefits of eplerenone in patients with systolic heart failure and mild symptoms when initiated shortly after hospital discharge: analysis from the EMPHASIS-HF trial. Eur Heart J
39. Santos J, Planas R, Pardo A, Durández R, Cabré E, Morillas RM, Granada ML, Jiménez JA, Quintero E, Gassull MA (2003) Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 39(2):187–192
40. Pérez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, Rivera F, Rodés J (1983) Randomized comparative study of efficacy of furosemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the rennin–aldosterone system. Gastroenterology 84(5 Pt 1):961–968
41. Hensen J, Abraham WT, Durr JA, Schrier RW (1991) Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 11(6):441–446
42. van Vliet AA, Donker AJ, Nauta JJ, Verheugt FW (1993) Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71(3):21A–28A
43. Overdiek HW, Merkus FW (1986) Influence of food on the bioavailability of spironolactone. Clin Pharmacol Ther 40(5):531–536
44. Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10(1):23–29
45. Ceremuzynski L, Budaj A, Michorowski B (1983) Single-dose i.v. Aldactone for congestive heart failure: a preliminary observation. Int J Clin Pharmacol Ther Toxicol 21(8):417–421
46. Felker GM, O’Connor CM, Braunwald E (2009) Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2(1):56–62
47. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005) Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149(2):209–216
48. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O’Connor CM (2011) Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364(9):797–805
49. Sarraf M, Masoumi A, Schrier RW (2009) Cardiorenal syndrome in acute decompensated heart failure. Clin J Am Soc Nephrol 4(12):2013–2026
50. Rossignol P, Zannad F (2013) Loop diuretics and ultrafiltration in heart failure. Expert Opin Pharmacother 14(12):1641–1648
51. Abdallah JG, Schrier RW, Edelstein C, Jennings SD, Wyse B, Ellison DH (2001) Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(−)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 12(7):1335–1341
52. Wang DJ, Gottlieb SS (2008) Diuretics: still the mainstay of treatment. Crit Care Med 36(1 Suppl):S89–S94
53. Testani JM, Cappola TP, McCauley BD, Chen J, Shen J, Shannon RP, Kimmel SE (2011) Impact of worsening renal function during the treatment of decompensated heart failure on changes in renal function during subsequent hospitalization. Am Heart J 161(5):944–949
54. Velavan P, Khan NK, Goode K, Rigby AS, Loh PH, Komajda M, Follath F, Swedberg K, Madeira H, Cleland JG (2010) Predictors of short term mortality in heart failure—insights from the Euro Heart Failure survey. Int J Cardiol 138(1):63–69
55. Vardeny O, Wu DH, Desai A, Rossignol P, Zannad F, Pitt B, Solomon SD (2012) Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). J Am Coll Cardiol 60(20):2082–2089
56. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, Tang WH (2014) Loop diuretic efficiency: a metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. Circ Heart Fail 7(2):261–270
57. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35(7):455–469